ES2063912T3 - Composiciones inmunogenicas frente a peptidos de gastrina. - Google Patents

Composiciones inmunogenicas frente a peptidos de gastrina.

Info

Publication number
ES2063912T3
ES2063912T3 ES90300456T ES90300456T ES2063912T3 ES 2063912 T3 ES2063912 T3 ES 2063912T3 ES 90300456 T ES90300456 T ES 90300456T ES 90300456 T ES90300456 T ES 90300456T ES 2063912 T3 ES2063912 T3 ES 2063912T3
Authority
ES
Spain
Prior art keywords
immunogenic compositions
disclosed
gastrine
peptides
compositions against
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90300456T
Other languages
English (en)
Inventor
Philip C Gevas
Stephen Grimes
Stephen L Karr Jr
Richard L Littenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aphton Corp
Original Assignee
Aphton Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/301,353 external-priority patent/US5023077A/en
Application filed by Aphton Corp filed Critical Aphton Corp
Application granted granted Critical
Publication of ES2063912T3 publication Critical patent/ES2063912T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/595—Gastrins; Cholecystokinins [CCK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPOSICIONES INMUNOGENICAS UTILES EN EL TRATAMIENTO DE ULCERAS O TUMORES CUYO CRECIMIENTO DEPENDA DE HORMONAS DE GASTRINA O SE ESTIMULE CON ELLAS. LAS COMPOSICIONES INMUNOGENICAS INDUCEN A LOS ANTICUERPOS DE UN SUJETO QUE NEUTRALICEN SELECTIVAMENTE LAS HORMONAS ESPECIFICAS. TAMBIEN SE REVELAN COMPOSICIONES FARMACEUTICAS QUE CONSTEN DE CANTIDADES EFECTIVAS DE LAS COMPOSICIONES INMUNOGENICAS Y METODOS DE TRATAMIENTO CON LAS MISMAS, ASI COMO UN METODO PARA INVERTIR LOS TRATAMIENTOS INVENTIVOS MEDIANTE LA NEUTRALIZACION DE LOS ANTICUERPOS INDUCIDOS "IN VIVO".
ES90300456T 1989-01-24 1990-01-17 Composiciones inmunogenicas frente a peptidos de gastrina. Expired - Lifetime ES2063912T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/301,353 US5023077A (en) 1989-01-24 1989-01-24 Immunogenic compositions and methods for the treatment and prevention of gastric and duodenal ulcer disease
US35119389A 1989-05-12 1989-05-12

Publications (1)

Publication Number Publication Date
ES2063912T3 true ES2063912T3 (es) 1995-01-16

Family

ID=26972322

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90300456T Expired - Lifetime ES2063912T3 (es) 1989-01-24 1990-01-17 Composiciones inmunogenicas frente a peptidos de gastrina.

Country Status (12)

Country Link
US (3) US5607676A (es)
EP (1) EP0380230B1 (es)
JP (1) JP2526418B2 (es)
AT (1) ATE114160T1 (es)
AU (1) AU645967B2 (es)
CA (1) CA2045594C (es)
DE (1) DE69014137T2 (es)
DK (1) DK0380230T3 (es)
ES (1) ES2063912T3 (es)
IE (1) IE66267B1 (es)
PT (1) PT92938B (es)
WO (1) WO1990008774A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023077A (en) * 1989-01-24 1991-06-11 Aphton Corporation Immunogenic compositions and methods for the treatment and prevention of gastric and duodenal ulcer disease
US6861510B1 (en) * 1989-01-24 2005-03-01 Aphton Corporation Immunogenic compositions against gastrin peptides
ATE114160T1 (de) * 1989-01-24 1994-12-15 Aphton Corp Immunogenische zusammensetzungen gegen gastrin- peptide.
US5468494A (en) * 1993-11-12 1995-11-21 Aphton Corp. Immunogenic compositions against human gastrin 17
US5688506A (en) * 1994-01-27 1997-11-18 Aphton Corp. Immunogens against gonadotropin releasing hormone
GB9406974D0 (en) * 1994-04-08 1994-06-01 Pharmaceutical Proteins Ltd Transgenic production
PT889735E (pt) * 1996-02-08 2011-07-19 Cancer Advances Inc Métodos imunológicos para o tratamento do cancro gastrointestinal
US6072086A (en) * 1996-04-12 2000-06-06 Intergen Company Method and composition for controlling formaldehyde fixation by delayed quenching
CA2288027A1 (en) * 1997-04-23 1998-10-29 The Regents Of The University Of Michigan Bradykinin analogs as selective inhibitors of cell activation
US6982249B1 (en) 1997-04-23 2006-01-03 The Regents Of The University Of Michigan Bradykinin analogs as selective inhibitors of cell activation
NZ500748A (en) * 1997-05-12 2001-06-29 Aphton Corp Methods for the treatment of gastrin-dependent tumours comprising active or passive immunisation with an anti-CCK-B/gastrin receptor immunogen or anti-CCK-B/gastrin receptor antibodies
US20040001842A1 (en) * 1997-05-12 2004-01-01 Dov Michaeli Immunogenic compositions to the CCK-B/gastrin receptor and methods for the treatment of tumors
WO1999059612A1 (en) * 1998-05-15 1999-11-25 Aphton Corporation Method for the treatment of gastroesophageal reflux disease
US20030068326A1 (en) * 1998-05-15 2003-04-10 Aphton Corporation Method for the treatment of gastroesophageal reflux disease
DE69935977T2 (de) * 1998-05-15 2008-01-10 Receptor Biologix, Inc., Palo Alto Vorbeugung und Behandlung von Hypergastrinämie
EP1897556A1 (en) * 1998-05-15 2008-03-12 Receptor Biologix, Inc. Prevention and treatment of hypergastrinemia
ES2237103T3 (es) * 1998-05-15 2005-07-16 Aphton Corporation Terapia de combinacion para el tratamiento de tumores.
EP1579863A3 (en) * 1998-05-15 2008-03-19 Receptor Biologix, Inc. Combination therapy with anti-gastrin G17 antibodies for the treatment of tumors
AU768612B2 (en) * 1998-06-18 2003-12-18 Vecta Ltd Pharmaceutical compositions for the treatment of (helicobacter pylori)-associated disorders
JP2005508838A (ja) * 2001-03-23 2005-04-07 アフトン コーポレーション 膵癌の組合せ治療
US20090191232A1 (en) 2001-05-04 2009-07-30 Gevas Philip C Combination therapy for the treatment of tumors
AU2002326356A1 (en) * 2001-07-09 2003-01-29 Aphton Corporation Treatment and prevention of cancerous and pre-cancerous conditions of the liver, lung and esophagus
EP1837031B1 (en) * 2002-06-07 2009-10-14 Waratah Pharmaceuticals, Inc. Compositions and methods for treating diabetes
US20050169979A1 (en) * 2002-07-03 2005-08-04 Dov Michaeli Liposomal vaccine
CA2501677A1 (en) * 2002-10-22 2004-05-06 Waratah Pharmaceuticals, Inc. Treatment of diabetes
US20080096824A1 (en) * 2003-02-28 2008-04-24 Shigemi Matsuyama Ku-70-derived bax-suppressing peptides and use thereof for the protection of damaged cells
US7235376B2 (en) 2003-03-28 2007-06-26 Receptor Biologix, Inc. Gastrin hormone immunoassays
CN1997669A (zh) * 2004-03-29 2007-07-11 受体生物技术公司 抗胃泌素激素单克隆抗体
WO2005095459A2 (en) * 2004-03-29 2005-10-13 Receptor Biologix, Inc. Monoclonal antibodies to gastrin hormone
EP2567974A3 (en) * 2004-09-22 2013-05-22 Cancer Advances, Inc., Monoclonal antibodies to progastrin
GB201121571D0 (en) * 2011-12-15 2012-01-25 Astrimmune Ltd Compounds and uses thereof
CN109806387B (zh) 2012-07-13 2022-03-04 S-目标疗法有限公司 免疫调节疫苗
JP6395816B2 (ja) * 2013-05-21 2018-09-26 ティーワイジー・オンコロジー・リミテッド ガストリンペプチド免疫原組成物
CA3066756A1 (en) 2017-06-15 2018-12-20 Cancer Advances Inc. Compositions and methods for inducing humoral and cellular immunities against tumors and cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3932242A (en) * 1957-11-21 1976-01-13 Bartley Charles E Solid propellant with butyl rubber binder
DE2256445C3 (de) * 1972-11-17 1981-11-05 Hoechst Ag, 6000 Frankfurt Heptapeptide, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Präparate
US4384995A (en) * 1980-01-16 1983-05-24 The Ohio State University Antigenic modification of polypeptides
US4526716A (en) * 1981-11-20 1985-07-02 The Ohio State University Antigenic modification of polypeptides
US4691006A (en) * 1983-03-04 1987-09-01 Ohio State University Antigenic modification of polypeptides
SU1414392A1 (ru) * 1982-12-29 1988-08-07 Всесоюзный кардиологический научный центр АМН СССР Противо звенное средство
FR2575164B1 (fr) * 1984-12-20 1987-03-20 Sanofi Sa Esters de tri- et tetrapeptides inhibiteurs de la secretion gastrique, procede d'obtention et compositions pharmaceutiques les contenant
US5023077A (en) * 1989-01-24 1991-06-11 Aphton Corporation Immunogenic compositions and methods for the treatment and prevention of gastric and duodenal ulcer disease
ATE114160T1 (de) * 1989-01-24 1994-12-15 Aphton Corp Immunogenische zusammensetzungen gegen gastrin- peptide.
US5468494A (en) * 1993-11-12 1995-11-21 Aphton Corp. Immunogenic compositions against human gastrin 17

Also Published As

Publication number Publication date
AU5082090A (en) 1990-08-24
EP0380230A3 (en) 1991-06-26
IE66267B1 (en) 1995-12-27
JP2526418B2 (ja) 1996-08-21
IE900250L (en) 1990-07-24
US5607676A (en) 1997-03-04
WO1990008774A1 (en) 1990-08-09
US5609870A (en) 1997-03-11
PT92938B (pt) 1996-09-30
JPH04503072A (ja) 1992-06-04
DK0380230T3 (da) 1995-01-16
US5785970A (en) 1998-07-28
CA2045594C (en) 2002-08-13
DE69014137T2 (de) 1995-06-08
ATE114160T1 (de) 1994-12-15
PT92938A (pt) 1990-07-31
EP0380230A2 (en) 1990-08-01
AU645967B2 (en) 1994-02-03
CA2045594A1 (en) 1990-07-25
DE69014137D1 (de) 1994-12-22
EP0380230B1 (en) 1994-11-17

Similar Documents

Publication Publication Date Title
ES2063912T3 (es) Composiciones inmunogenicas frente a peptidos de gastrina.
ATE60697T1 (de) Verfahren zur bekaempfung von pilzen.
DE69010893D1 (de) Verfahren zur behandlung von koks sowie löschen desselben.
DE69231294D1 (de) Vorrichtung zur behandlung von tumoren
NO933126D0 (no) Loeselige ligander for cd40
DE69303803D1 (de) Behandlungsmethode zur Bodenverfestigung
DE3856594D1 (de) Mittel zur behandlung der alzheimer-krankheit
DK90888A (da) Maaleapparat til vaevsmetabolisme
ES2013631B3 (es) Metodo para el tratamiento de tejidos.
DE68917433D1 (de) Verfahren zur behandlung von asbest sowie asbestbehandlungsmittel.
DE3854121D1 (de) Arzneimittelzusammensetzungen zur behandlung von psoriasis.
DE3856329D1 (de) Verwendung von Ethisterone zur topischen Behandlung von Akne oder androgenetischer Alopezie
DE69818809D1 (de) Verfahren zur behandlung von narbengewebe
ATE181240T1 (de) Verwendung von somatostatinanalogen zur behandlung von melanomen
NO880292D0 (no) Fremgangsmaate for behandling av humle.
DE3873846D1 (de) Behandlungsapparat und verfahren.
BR9007738A (pt) Metodo de tratamento de couros
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
MX9200755A (es) Tratamiento de carcinoma pulmonar de celulas no pequeñas.
DE68909750D1 (de) Vorrichtung zur therapeutischen behandlung von lumbago sowie lumbago/ischias.
DE3878137D1 (de) Behandlungsmethode zur bodenstabilisierung.
SU619185A1 (ru) Способ лечени злокачественных опухолей органов малого таза
NO905345D0 (no) Fremgangsmaate og innretning for behandling av elektroforesebaerere.
ATA176389A (de) Verfahren und einrichtung zur stoffbehandlung bzw. -reaktion
EP0321094A3 (en) Treatment of factor viii inhibitors

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 380230

Country of ref document: ES